Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Herpetic reactivation during radiotherapy treatment for gynaecological cancers-a retrospective observational study.
Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerpes simplex virus (HSV) and varicella zoster virus (VZV) remain latent in sensory ganglia and can reactivate under immunosuppressive states such as cancer therapy. Radiotherapy-induced local immune suppression may increase the risk of herpes reactivation, leading to treatment interruptions and suboptimal outcomes. Evidence on the incidence and determinants of herpes reactivation among gynaecologic cancer patients undergoing radiotherapy remains limited.
methodsA retrospective observational study was conducted at St. John's Medical College Hospital, including women ≥ 18 years with histologically confirmed gynaecologic malignancies treated with definitive or adjuvant radiotherapy between January 2016 and October 2025. Demographic, clinical, treatment-related characteristics, and comorbidities were analyzed. The study aimed to determine the incidence of HSV/VZV reactivation during radiotherapy, evaluate associated risk factors.
resultsAmong 391 patients analyzed, herpes reactivation occurred in 5.6% (22 patients). All reactivations occurred in patients with carcinoma of uterine cervix (7.6% (22/291); p = 0.018), with no HRA in other gynaecologic cancers. Higher EBRT dose (p = 0.020), use of VMAT/IMRT techniques (p = 0.008), concurrent chemotherapy (8.1% vs 0%, p = 0.002) and presence of STIs (Sexually Transmitted Infections) (27.8% (5/18) versus 4.6% (17/373); p < 0.001) were associated with significantly increased risk. Interestingly, the patients treated post COVID 19 pandemic were more likely to develop reactivation that those treated before pandemic (8.8% vs 1.7%; p = 0.002). 53.3% of the treatment interruptions were attributable to HRAs.
conclusionHerpes virus reactivation during radiotherapy for gynecologic cancers is a significant cause of treatment interruption. Carcinoma uterine cervix and presence of other STIs are significant risk factors. There is higher incidence of reactivations in the post COVID era.
Indexed as
Identifiers
42665708What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.